Dr Boreham’s Crucible: Revenge of the nerd – Percheron’s new boss takes on cancer

Résumé détaillé
Self-confessed science nerd Dr Michael Baker has restarted the engine of Percheron Therapeutics with the aim of getting the oncology ... Read More The post Dr Boreham’s Crucible:…
Percheron has revived itself as an oncology play. Pic: Tim Boreham/supplied
Dr Michael Baker, the new CEO of Percheron Therapeutics (ASX:PER), describes himself as “pretty boring, but in a good way”.
“I just love high-quality science with a disproportionate chance of success in a field I have a tremendous interest in.”
Boring? We would still strike up a chat with him at a party, albeit after a second drink.
This alleged dullness made Baker a walk-up start to head Percheron, which has revived itself as an oncology play after a catastrophic Duchenne muscular dystrophy trial (see below).
Baker was fresh from a six-year stint at Arovella Therapeutics, which he re-engineered from unsuccessful spray-delivery drug play Suda Pharmaceuticals to an early-stage cancer cell therapy developer.
Baker’s Percheron appointment is also notable because he eschewed a number of better-paid, bigger roles for the buzz of early-stage drug development.
“I don’t want to sound like a twerp, but I was quite lucky in that I got a number of opportunities to explore and some of them were quite sizeable,” he said.
“They had a lot of money, [but] I actually didn’t find it all that interesting.
Début de l'article, extrait de Stockhead. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (stockhead.com.au)




